Assessment of the ocular response to topical beta-adrenoceptor antagonists using accommodative microfluctuations.
Power spectrum analysis of accommodative microfluctuations has identified two dominant frequency components: a low frequency component (LFC < 0.6 Hz) and a high frequency component (1.3 Hz < HFC < 2.5 Hz). Computer-driven models of accommodation and experimental manipulation of accommodative feedback loops indicate that LFCs are likely to have a functional role in monitoring retinal image contrast during sustained accommodation. In contrast HFCs have been shown to be correlated with arterial pulse frequency and consequently their characteristics can be modified by the extra- and intra-ocular vascular (and possibly CNS) effects. For example, topical instillation of the non-selective beta-antagonist timolol maleate has shown previously the ability to modify the HFC. In an attempt to clarify proposed differences between beta-adrenoceptor antagonist agents with regard to their effects on systemic and ocular vasculature, we extend the potential offered by HFCs as a non-invasive method of assessing the ocular response to beta-antagonists to the cardioselective beta-antagonist betaxolol HCl. Accommodative microfluctuations were measured using a continuously recording infrared optometer on 10 emmetropic subjects (mean age 23.9 +/- 2.3 years) who viewed a high contrast target located at a vergence of -4 D. A double-blind protocol was employed between saline and betaxolol (0.5%, 2 x 30 microliters) following corneal anaesthesia. Local and systemic effects were separated by examining the treated and untreated eyes of three subjects. Power spectrum analysis indicated that the root mean square (r.m.s.) value and power of LFCs and HFCs were equivalent for the saline and betaxolol trials.(ABSTRACT TRUNCATED AT 250 WORDS)
Strang
N C
NC
Department of Vision Sciences, Glasgow Caledonian University, UK.
Winn
B
B
Gilmartin
B
B
Brosnahan
D
D
D000065:Accommodation, Ocular / Q000187:drug effects*; D000287:Administration, Topical; D000328:Adult; D015784:Betaxolol / Q000008:administration & dosage / Q000494:pharmacology*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects; D008297:Male; D013997:Time Factors; D013999:Timolol / Q000494:pharmacology
D013999:Timolol; D015784:Betaxolol